230 related articles for article (PubMed ID: 25065532)
1. Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes.
Hsiao CH; Lin X; Barney RJ; Shippy RR; Li J; Vinogradova O; Wiemer DF; Wiemer AJ
Chem Biol; 2014 Aug; 21(8):945-54. PubMed ID: 25065532
[TBL] [Abstract][Full Text] [Related]
2. HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.
Kilcollins AM; Li J; Hsiao CH; Wiemer AJ
J Immunol; 2016 Jul; 197(2):419-28. PubMed ID: 27271567
[TBL] [Abstract][Full Text] [Related]
3. A Structural Change in Butyrophilin upon Phosphoantigen Binding Underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell Activation.
Yang Y; Li L; Yuan L; Zhou X; Duan J; Xiao H; Cai N; Han S; Ma X; Liu W; Chen CC; Wang L; Li X; Chen J; Kang N; Chen J; Shen Z; Malwal SR; Liu W; Shi Y; Oldfield E; Guo RT; Zhang Y
Immunity; 2019 Apr; 50(4):1043-1053.e5. PubMed ID: 30902636
[TBL] [Abstract][Full Text] [Related]
4. A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.
Li J; Lentini NA; Wiemer DF; Wiemer AJ
Biochem Pharmacol; 2019 Dec; 170():113668. PubMed ID: 31628909
[TBL] [Abstract][Full Text] [Related]
5. A Photo-Crosslinkable Biotin Derivative of the Phosphoantigen (E)-4-Hydroxy-3-Methylbut-2-Enyl Diphosphate (HMBPP) Activates Vγ9Vδ2 T Cells and Binds to the HMBPP Site of BTN3A1.
Mattarei A; Enzinger M; Gu S; Karunakaran MM; Kimmel B; Berner N; Adams EJ; Herrmann T; Amslinger S
Chemistry; 2017 Sep; 23(49):11945-11954. PubMed ID: 28631855
[TBL] [Abstract][Full Text] [Related]
6. Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.
Shippy RR; Lin X; Agabiti SS; Li J; Zangari BM; Foust BJ; Poe MM; Hsiao CC; Vinogradova O; Wiemer DF; Wiemer AJ
J Med Chem; 2017 Mar; 60(6):2373-2382. PubMed ID: 28218845
[TBL] [Abstract][Full Text] [Related]
7. Alpaca (
Fichtner AS; Karunakaran MM; Gu S; Boughter CT; Borowska MT; Starick L; Nöhren A; Göbel TW; Adams EJ; Herrmann T
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6697-6707. PubMed ID: 32139608
[TBL] [Abstract][Full Text] [Related]
8. Structure-Activity Relationships of Butyrophilin 3 Ligands.
Wiemer AJ
ChemMedChem; 2020 Jun; 15(12):1030-1039. PubMed ID: 32453919
[TBL] [Abstract][Full Text] [Related]
9. Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.
Moulin M; Alguacil J; Gu S; Mehtougui A; Adams EJ; Peyrottes S; Champagne E
Cell Mol Life Sci; 2017 Dec; 74(23):4353-4367. PubMed ID: 28669030
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of ( E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses.
Davey MS; Malde R; Mykura RC; Baker AT; Taher TE; Le Duff CS; Willcox BE; Mehellou Y
J Med Chem; 2018 Mar; 61(5):2111-2117. PubMed ID: 29457898
[TBL] [Abstract][Full Text] [Related]
11. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation.
Gu S; Sachleben JR; Boughter CT; Nawrocka WI; Borowska MT; Tarrasch JT; Skiniotis G; Roux B; Adams EJ
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7311-E7320. PubMed ID: 28807997
[TBL] [Abstract][Full Text] [Related]
12. The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.
Peigné CM; Léger A; Gesnel MC; Konczak F; Olive D; Bonneville M; Breathnach R; Scotet E
J Immunol; 2017 Jun; 198(11):4228-4234. PubMed ID: 28461569
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic and antioxidant effects of a pathogen-associated prenyl pyrophosphate in Anopheles gambiae.
Lindberg BG; Merritt EA; Rayl M; Liu C; Parmryd I; Olofsson B; Faye I
PLoS One; 2013; 8(8):e73868. PubMed ID: 23967351
[TBL] [Abstract][Full Text] [Related]
14. F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells.
Mookerjee-Basu J; Vantourout P; Martinez LO; Perret B; Collet X; Périgaud C; Peyrottes S; Champagne E
J Immunol; 2010 Jun; 184(12):6920-8. PubMed ID: 20483757
[TBL] [Abstract][Full Text] [Related]
15. TCR repertoire analysis reveals phosphoantigen-induced polyclonal proliferation of Vγ9Vδ2 T cells in neonates and adults.
Fichtner AS; Bubke A; Rampoldi F; Wilharm A; Tan L; Steinbrück L; Schultze-Florey C; von Kaisenberg C; Prinz I; Herrmann T; Ravens S
J Leukoc Biol; 2020 Jun; 107(6):1023-1032. PubMed ID: 32064671
[TBL] [Abstract][Full Text] [Related]
16. A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.
Hsiao CC; Wiemer AJ
Biochem Pharmacol; 2018 Dec; 158():298-304. PubMed ID: 30391478
[TBL] [Abstract][Full Text] [Related]
17. The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.
Nguyen K; Li J; Puthenveetil R; Lin X; Poe MM; Hsiao CC; Vinogradova O; Wiemer AJ
FASEB J; 2017 Nov; 31(11):4697-4706. PubMed ID: 28705810
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists.
Wiemer DF; Wiemer AJ
Biochem Pharmacol; 2014 Jun; 89(3):301-12. PubMed ID: 24680696
[TBL] [Abstract][Full Text] [Related]
19. ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.
Riganti C; Castella B; Massaia M
Front Immunol; 2018; 9():1246. PubMed ID: 29937767
[TBL] [Abstract][Full Text] [Related]
20. Potent double prodrug forms of synthetic phosphoantigens.
Harmon NM; Huang X; Schladetsch MA; Hsiao CC; Wiemer AJ; Wiemer DF
Bioorg Med Chem; 2020 Oct; 28(19):115666. PubMed ID: 32912439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
